Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SAN DIEGO, Feb. 20, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.
CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CrownBio, a leader in the field of preclinical immuno-oncology research, offers a CAR T-cell platform for proof-of-concept and therapeutic efficacy validation. Clinically relevant in vivo and in vitro models combine with a comprehensive suite of analytical services to enable efficient, early evaluation of CAR T-cell agents. The addition of bioluminescence imaging (BLI) for non-invasive evaluation of systemic and orthotopic tumor progression, in real-time, further enhances an already robust platform and provides a unique set of solutions to advance CAR T-cell therapies.
“We are committed to delivering innovative services to help our clients’ develop improved cancer therapeutics,” said Dr. Rajendra Kumari, CrownBio’s Chief Scientific Officer, UK. “Our non-invasive BLI capabilities, applied to CAR T-cell evaluation platform, deliver cutting-edge in vivo data that helps drug developers uncover insights to guide successful downstream development and clinical application of CAR T-cell agents.”
Learn more about CrownBio’s CAR T-cell evaluation platform at https://www.crownbio.com/oncology/immuno-oncology/car-t-cell-therapy-models/
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
